Inhibrx Inc
NASDAQ:INBX
Intrinsic Value
Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. [ Read More ]
The intrinsic value of one INBX stock under the Base Case scenario is 25.95 USD. Compared to the current market price of 34.61 USD, Inhibrx Inc is Overvalued by 25%.
Valuation Backtest
Inhibrx Inc
Run backtest to discover the historical profit from buying and selling INBX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Inhibrx Inc
Current Assets | 295.4m |
Cash & Short-Term Investments | 277.9m |
Receivables | 778k |
Other Current Assets | 16.7m |
Non-Current Assets | 12.5m |
PP&E | 9.4m |
Other Non-Current Assets | 3.2m |
Current Liabilities | 56.3m |
Accounts Payable | 11m |
Accrued Liabilities | 45.4m |
Non-Current Liabilities | 208.1m |
Long-Term Debt | 207m |
Other Non-Current Liabilities | 1.1m |
Earnings Waterfall
Inhibrx Inc
Revenue
|
1.8m
USD
|
Operating Expenses
|
-221m
USD
|
Operating Income
|
-219.2m
USD
|
Other Expenses
|
-22.1m
USD
|
Net Income
|
-241.4m
USD
|
Free Cash Flow Analysis
Inhibrx Inc
What is Free Cash Flow?
INBX Profitability Score
Profitability Due Diligence
Inhibrx Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
Score
Inhibrx Inc's profitability score is 29/100. The higher the profitability score, the more profitable the company is.
INBX Solvency Score
Solvency Due Diligence
Inhibrx Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Score
Inhibrx Inc's solvency score is 31/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
INBX Price Targets Summary
Inhibrx Inc
According to Wall Street analysts, the average 1-year price target for INBX is 36.21 USD with a low forecast of 35.35 USD and a high forecast of 37.8 USD.
Ownership
INBX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
INBX Price
Inhibrx Inc
Average Annual Return | 14.54% |
Standard Deviation of Annual Returns | 52.89% |
Max Drawdown | -83% |
Market Capitalization | 1.6B USD |
Shares Outstanding | 47 392 400 |
Percentage of Shares Shorted | 6.95% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Inhibrx, Inc., is a clinical stage biotechnology company, focuses on developing pipeline of novel biologic therapeutic candidates. The company is headquartered in La Jolla, California and currently employs 106 full-time employees. The company went IPO on 2020-08-19. The Company’s single domain antibody (sdAb) platform provides a small, simple, modular target binding domain that can be combined in to meet the needs of each biological target. Its products pipeline includes: INBRX-101 is a recombinant alpha-1 antitrypsin (AAT) protein that is comprised of two human AAT, molecules covalently linked to the fragment crystallizable (Fc) region of human immunoglobulin G4; INBRX-109 is a precisely engineered tetravalent sdAb-based therapeutic candidate targeting death-receptor 5 (DR5) that designed with its sdAb platform to drive cancer-selective programmed cell death and to maximize potency while minimizing on-target liver toxicity arising from hepatocyte apoptosis, and INBRX-105 is a precisely engineered multi-specific sdAb-based therapeutic candidate that is designed to agonize 4-1BB selectively in the presence of PD-L1.
Contact
IPO
Employees
Officers
The intrinsic value of one INBX stock under the Base Case scenario is 25.95 USD.
Compared to the current market price of 34.61 USD, Inhibrx Inc is Overvalued by 25%.